CFSAN committee proposes dedicated cosmetics review
This article was originally published in The Rose Sheet
Executive Summary
Following a review of the Center for Food Safety and Applied Nutrition's research, support programs and regulatory activities, FDA's advisory Science Board and CFSAN Research Review Subcommittee have recommended that a separate review be conducted of the Office of Cosmetics. At Aug. 16 Science Board meeting in Bethesda, Md., discussion of the Office of Cosmetics was limited by time and lack of a cosmetics review "point person" since Larry Sasich of the Lake Erie College of Osteopathic Medicine and School of Pharmacy recently stepped down from his position as the Science Board's consumer representative, according to Science Board member Rhona Applebaum. While subcommittee is "impressed" with cosmetics office's collaboration with regulators in the EU, Canada and Japan through the International Cooperation for Cosmetics Regulation, it is not clear on regulatory framework for cosmetics in the U.S. and could use more information, particularly in light of recent questions raised by the Campaign for Safe Cosmetics. The Campaign is championing legislation, H.R. 5786, that would dramatically increase FDA's regulatory authority over cosmetics (1"The Rose Sheet" July 26, 2010)
You may also be interested in...
House's "Safe Cosmetics Act" Seeks End To Industry "Free Reign"
Dubbed the "Safe Cosmetics Act of 2010," a bill introduced last week would dramatically overhaul personal-care regulation, requiring companies that manufacture, package or distribute cosmetics for use in the U.S. to register with FDA and provide the agency with a wealth of information about their product formulations and business practices
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.